Repeated Acoustic Vaporization of Perfluorohexane Nanodroplets for Contrast-Enhanced Ultrasound Imaging

Austin Van Namen, Student Member, IEEE, Sidhartha Jandhyala, Student Member, IEEE, Tomas Jordan, Student Member, IEEE, and Geoffrey Luke, Member, IEEE

Abstract—Superheated perfluorocarbon nanodroplets are emerging ultrasound imaging contrast agents boasting biocompatible components, unique phase-change dynamics, and therapeutic loading capabilities. Upon exposure to a sufficiently high intensity pulse of acoustic energy, the nanodroplet’s perfluorocarbon core undergoes a liquid-to-gas phase change and becomes an echogenic microbubble, providing ultrasound contrast. The controllable activation leads to high-contrast images, while the small size of the nanodroplets promotes longer circulation times and better in-vivo stability. One drawback, however, is that the nanodroplets can only be vaporized a single time, limiting their versatility. Recently, we and others have addressed this issue by using a perfluorohexane core, which has a boiling point above body temperature. Thus after vaporization, the microbubbles recondense back into their stable nanodroplet form. Previous work with perfluorohexane nanodroplets relied on optical activation via pulsed laser absorption of an encapsulated dye. This strategy limits the imaging depth and temporal resolution of the method. In this study we overcome these limitations by demonstrating acoustic droplet vaporization with 1.1-MHz high-intensity focused ultrasound. A short-duration, high-amplitude pulse of focused ultrasound provides a sufficiently strong peak negative pressure to initiate vaporization. A custom imaging sequence was developed to enable the synchronization of a HIFU transducer and a linear array imaging transducer. We show visualization of repeated acoustic activation of perfluorohexane nanodroplets in polyacrylamide tissue-mimicking phantoms. We further demonstrate detection of hundreds of vaporization events from individual nanodroplets with activation thresholds well below the tissue cavitation limit. Overall, this approach has the potential to result in reliable and repeatable contrast-enhanced ultrasound imaging at clinically relevant depths.

Index Terms—acoustic droplet vaporization, high intensity focused ultrasound, phase change contrast agents, perfluorocarbon nanodroplets

I. INTRODUCTION

GASEOUS microbubbles augment the diagnostic and therapeutic potential of ultrasound imaging for a wide variety of applications, such as vascular mapping, lithotripsy, targeted drug delivery, tissue ablation, and clot disruption [1]–[8]. The large acoustic impedance mismatch between the gaseous core of the microbubbles and the water-based tissue background produces ultrasound contrast. The contrast can be further enhanced by harnessing the nonlinear acoustic response of microbubbles with novel ultrasound image acquisition strategies, such as harmonic imaging or pulse inversion [9]–[11]. The typical size of a microbubble contrast agent is between 1-10 µm in diameter which restricts these contrast agents to the vasculature and leads to fast clearance from the body. Contrast agents with a nanometer-scale diameter, however, allow for extravasation into the leaky, disorganized vasculature of tumors. Extravasation of contrast agents enhances ultrasound’s potential for molecular tumor-specific targets [12].

Sub-micron phase change particles, such as perfluorocarbon nanodroplets (PFCnDs), were created in a push to decrease contrast agent size in order to promote tumor extravasation and enhance in-vivo stability [13]. PFCnDs consist of a liquid perfluorocarbon core and a stabilizing shell. In their innate liquid nanodroplet state, the PFCnDs do not provide ultrasound contrast; however, they can be optically or acoustically activated to undergo a liquid to gas phase change and form micron-sized bubbles. Optical activation is produced through absorption of laser energy by a photoabsorber embedded in the nanodroplet [14]. Acoustic activation, referred to as acoustic droplet vaporization (ADV), is achieved by exposing the PFCnDs to a negative acoustic pressure below a threshold amplitude, initiating the phase change [15]. A sufficient peak negative pressure (PNP) allows the HnDs to vaporize by overcoming both the PFC vaporization pressure and the Laplace pressure exerted by the lipid shell on the PFC liquid core. Some groups have shown this pressure threshold can be decreased through innovative strategies such as incorporating nucleation sites and multi-modal activation [16]–[18]. The unique dynamics of PFCnDs have enabled their use in a wide range of applications including super-resolution imaging, disruption of the blood-brain barrier, vascular imaging, and targeted drug delivery [19]–[23]. Typically a low-boiling-point perfluorocarbon (e.g., perfluorobutane or perfluoropentane with a boiling point of -2 °C or 28 °C, respectively) is used so that the activation energy triggers irreversible vaporization. Thus, PFCnDs are activatable, nano-sized contrast agents that have the potential for improved biodistribution properties [15], [24]–[27].

Although low-boiling-point PFCnDs are a promising alternative to microbubbles, additional benefits can be achieved by using a core with a higher boiling point. We and others have proposed using perfluorohexane as the core of the PFCnDs [19], [28]–[33]. Perfluorohexane has a longer carbon chain length which leads to a boiling point of 56 °C. The higher boiling point results in two related phenomena. First, the activation threshold is higher; more energy is needed to vaporize the...
particles. Second, because the boiling point is above that of the surrounding tissue, the perfluorohexane nanodroplets (HnDs) recondense back to their stable liquid nanodroplet form a short time after each vaporization event [28], [32], [34]–[36]. Thus, the vaporization can be repeated. An illustration and example of this phenomenon is depicted in Figure 1.

The repeatable vaporization of high-boiling-point HnDs offers several benefits. When applied to in-vivo imaging, the HnDs will be less volatile than their lower boiling point counterparts, which could lead to longer circulation times and extended imaging windows. In addition, each nanodroplet can be activated and imaged multiple times. This repeated vaporization can be used to suppress the background tissue and boost the sensitivity of the method [28]. The dynamic contrast could also be leveraged to employ super-resolution imaging methods [19]. Importantly, the improved resolution can be achieved with stationary HnDs, rather than relying on flowing microbubbles, potentially enabling high-resolution molecular imaging of bound HnDs [37].

![Figure 1. HnD vaporization and recondensation process. Due to the high boiling point of the perfluorohexane, the gaseous microbubble returns to its nanodroplet form on the order of milliseconds.](image)

We have previously shown that, when an optically absorbing dye is encapsulated in the HnDs, a laser pulse can reliably initiate the vaporization event [19], [28]. Although laser vaporization of the HnDs can result in reliable and repeatable activation of the contrast agents, the method has limitations in how it can be applied. Optical activation is limited by the pulse repetition rate of the laser (typically 10-20 Hz). Additionally, absorption and scattering in tissue of near-infrared light limit the depth of HnD vaporization. Previous work shows diminished HnD activity after 5 mm for HnDs with near-infrared absorbing dyes [19]. With human skin thickness varying between 1-4 mm, optical activation of HnDs works well for small animal models but would be restricted to superficial clinical applications. For applications deeper in tissue than 1 cm, ultrasound travels through tissue with minimal attenuation. While an acoustic activation strategy could overcome these limitations, ADV of HnDs remains a challenge. The relatively high vaporization threshold makes it difficult to vaporize the HnDs with an imaging transducer.

High-intensity focused ultrasound (HIFU) is currently used in the clinic for primarily therapeutic applications [38]–[40]. It has been shown to deliver both mechanical energy and localized heating in a contained volume centimeters deep in tissue. If high-amplitude, short pulses are applied, then inertial cavitation can occur and the resulting microbubbles can be used to mechanically disrupt the tissue, a technique known as lithotripsy or histotripsy [4], [6], [41]. These techniques have been shown to result in negligible deposition of thermal energy [42], [43]. Conversely, if excitation pulses with a longer duty cycle are used, then the tissue can be thermally ablated. Beyond mechanical and thermal ablation, focused ultrasound has been applied at lower pressure levels for applications including neuromodulation and physical therapy [44], [45].

High-intensity focused ultrasound is commonly applied at depths of several centimeters, thereby expanding the potential applications of HnDs beyond what can be achieved with an optical stimulus [38]–[40]. In addition, HIFU can be safely applied at kHz pulse repetition rates [46]. Faster acquisition of the HnD images would enable improved detection sensitivity through averaging, better suppression of tissue motion, and visualization of faster biological processes, such as blood flow.

The approach detailed in this paper harnesses HIFU energy to combine the benefits of repeatedly vaporized HnDs with the advantages of ADV. The HIFU pulses used for HnD vaporization have been designed with a low duty cycle (to avoid heating) [42], [43] and a PNP below the cavitation threshold (to avoid mechanical damage) [24], [47], [48]. We have developed methods and imaging sequences to clearly visualize HnDs undergoing repeated ADV. We have conducted studies to identify the HIFU thresholds for ADV of HnDs, characterize the resulting ultrasound imaging signal, and investigate the stability of the HnDs when undergoing multiple vaporization-recondensation cycles. Overall, by using HIFU as the ADV stimulus, HnDs could be more broadly applied to the diverse and growing range of applications which utilize phase-change nanodroplets.

II. MATERIALS AND METHODS

A. Nanodroplet Fabrication

Perfluorocarbon nanodroplets were fabricated using methods adapted from a previously published thin film hydration method [49], [50]. Precursor lipid films were comprised of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (16:0 PC (DPPC), 25 mg/mL in chloroform, Product Code: 850355C, Avanti Polar Lipids Inc, Alabaster, AL, USA) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG(2000), 25 mg/mL in chloroform, Product Code: 880128C, Avanti Polar Lipids Inc, Alabaster, AL, USA) in a volume ratio of 90:10...
DPPC to DSPE-PEG (34.4:1 mole ratio). 200 µL of the lipid mixture and 4 mL of chloroform (99.8% chloroform ACS reagent stabilized with ethanol, CAS 67-66-3, Oakwood Chemical Inc, Estill, SC, USA). The flask was then connected to a rotary evaporator (Heidolph, Schwabach, Germany) and spun at 50 rpm under vacuum at 250 mbar in a 37.5 °C water bath. This was done until the chloroform evaporated completely, leaving a lipid cake in the flask. The lipid cake was then resuspended in 4 ml of phosphate-buffered saline (PBS 1x, 21-040-CV, Corning, Corning, NY, USA) using a water bath sonicator (Symphony, VWR, Radnor, PA, USA) at room temperature for 30 seconds. The solution was then transferred to a scintillation vial and 250 µL of liquid perfluorocarbon was added. Either perfluoropentane (APF-29M (n-Dodecafluoropentane, 99.0%), Fluoromed, Round Rock, TX, USA), perfluorohexane (APF-60M (Perfluorohexanes, 99.0%), Fluoromed, Round Rock, TX, USA) or perfluorooctyl bromide (Perfluorooctyl bromide, 99%, ACROS Organics, Fair Lawn, NJ, USA) were used to make PnDs, HnDs and OBnDs respectively. The lipid and perfluorocarbon solution was then sonicated using a microtip sonicator (Q700 with a 3.2 mm tip, QSonica, Newton, CT, USA) to generate PFCnDs. The total sonication energy supplied to the solution was 10 J over the course of 5 seconds. Sonication was performed with the solution vial submerged in an ice bath to prevent heating. The PFCnDs were centrifuged (Mini-spin, Cat. No. 022620100, Eppendorf, Hamburg, Germany) and washed twice at 4293 × g RCF (Relative Centrifugal Force) for 1 minute to remove excess reagents in the supernatant. Finally, the nanodroplet pellet was resuspended in 5 ml of 0.5x PBS in water.

B. Experimental Setup

Both the tissue-mimicking phantoms and the HIFU transduction cone in this study were constructed using a polyacrylamide (PA) hydrogel. PA phantoms have been shown to be both optically and acoustically transparent compared to other tissue mimicking substances. The PA phantoms are well suited for HIFU studies and were selected because of tissue mimicking properties of soft tissue, including low acoustic attenuation (1-5 dB/cm), comparable speed of sound (1500-1600 m/s) and highly tunable elasticity (1-400 kPa) [51]–[54]. This study did not supplement the phantom with acoustic or optical scatterers or absorbers in order to more clearly visualize and investigate HnD behavior. Several published nanodroplet studies have used PA phantoms as a suitable phantom to study vaporization [35], [54]–[57].

Phantom preparation was conducted at room temperature inside a fume hood. The PA hydrogel was fabricated in a glass beaker on a magnetic stir plate operating at 100 rpm. To make 50 ml of the hydrogel, 33.3 ml of polyacrylamide solution (acrylamide/bis-acrylamide 29:1 30%, A3574, Sigma, St. Louis, MO, USA) and 500 µL of 10% w/v aqueous ammonium persulfate (A3678, Sigma, St. Louis, MO, USA) were added to 16.7 ml deionized water. The solution was then degassed in a water bath sonicator for 30 seconds to remove trapped bubbles in the phantom. 50 µl of TEMED (N,N,N',N' - tetramethyl - ethylenediamine, Sigma, St. Louis, MO, USA) was added as a crosslinking catalyst. When making the PFCnD phantoms, the deionized water contained 500 µl of PFCnD from the stock solution. The resulting PFCnD concentration in the phantom is therefore 100x diluted from the stock solution. To make the phantoms, 50 mL of crosslinked PFCnD phantom solution was pipetted into a 3D-printed (Lulzbot Mini, Lulzbot, ND, USA) 7 cm in length, 3 cm in width, and 2.5 cm in height phantom mold. The long rectangular shape was chosen for the portion of experiments where multiple imaging areas were required on a single phantom such as those shown in Figure 5. The PA hydrogel was then set for 10 minutes in a -80 °C freezer to counteract the exothermic effects of the polymerization from affecting the PFCnDs.

For the HIFU transduction cone, 200 ml of non-PFCnD phantom solution was pipetted into a 3D printed mold to create the cone shown in Figure 2. The 3D printed mold was created using the geometry of the HIFU transducer. The resulting conical phantom is a 9-cm tall truncated cone with a base radius of 4 cm that tapers to a 0.5 cm radius at the peak. The bottom of the cone phantom is rounded to match the HIFU transducer curvature in order to provide solid contact for ultrasound transduction. A custom-designed, 3D printed apparatus aligned the HIFU system and cone to achieve a consistent focal spot in the ultrasound images is shown in Figure 2(b). This focal spot occurs at 1.5 cm from the imaging transducer and 10 cm from the HIFU transducer, which correlates to 1 cm into the PFCnD phantom. The imaging transducer snapped into a rigid holder on 3D a printed stage to achieve consistent imaging across experiments. All 3D printed parts were printed using Polylactic Acid (PLA+, eSun, Shenzhen, China). All 3D printed files are available for
C. Ultrasound Imaging

A Verasonics Vantage 256 ultrasound imaging system was used to acquire ultrasound images and synchronize the triggering of the single-element HIFU transducer. The images were acquired with a 256-element 15-MHz capacitive micromachined linear array transducer (L22-8v, Verasonics, Kirkland, WA, USA). The imaging transducer and the phantom were coupled using ultrasound gel. The Verasonics hardware control and image processing were performed using Matlab (R2017b, Mathworks, Natick, MA, USA). Each B-mode ultrasound image was acquired using a plane-wave transmission from 5 steering angles equally spaced between -18 ° and 18 °. The plane wave utilized the center 128 transducer elements as transmit and receive channels for each acquisition. A 38-µs delay separated each steering angle acquisition. The maximum PNP measured for the B mode imaging was 0.28 MPa with an MI of 0.07, which should have little effect on the nanodroplets or microbubbles. Representative B-mode ultrasound images of HnD vaporization are shown in Figure 3(a). Ultrasound frames were acquired at a rate of 2 kHz. This timing was heuristically chosen to capture HnD vaporization and recondensation kinetics.

D. Activation of PFCnDs

The ultrasound image acquisition was synchronized with the HIFU by a digital trigger signal output from the Verasonics system. The single element HIFU transducer (H-151, Sonic Concepts, Bothell, WA, USA) has a focal depth of 100 mm, a focal width diameter of 2.17 mm and a z-plane focal length of 24.97 mm. The focal width diameter of the HIFU transducer closely matches the 2 mm diameter of the vaporized nanodroplet region shown in Figure 3(b). The transducer was powered by a radiofrequency power amplifier (1020L RF amplifier, E & I, Rochester, NY, USA) connected to an impedance matching circuit. For the HIFU setup, the trigger was received by an arbitrary waveform generator (Tektronix, Beaverton, OR, USA), which created a 10 cycle, 1.1-MHz sinusoid burst. The waveform was then amplified by a 200-W radio frequency power amplifier (1020L, E & I). The peak negative pressure (PNP) emitted from the HIFU was controlled by the amplitude of the waveform from the function generator. PNP measurements resulting from the power amplifier were calibrated using a needle hydrophone (Model HNA, ONDA, Sunnyvale, CA, USA). Hydrophone characterization of the HIFU transducer and PA coupling cone was carried out in a degassed water bath. The hydrophone was positioned at a distance of 10 cm from the HIFU transducer and raster scanned to find the center of the focus. The HIFU activation occurred immediately after the first B-mode ultrasound image. A 500-µs delay between frames ensured the HIFU would not be detected in the ultrasound frame immediately following the HIFU pulse.

E. Image Reconstruction and Processing

The beamforming and compounding were performed by Verasonics reconstruction algorithms. Due to the image reconstruction time, image reconstruction and data processing was handled asynchronously with respect to acquisition. A band pass filter was applied during the acquisition process centered at 18 MHz with a 77 percent bandwidth using the Verasonics filter tool. Images were formed of a single 2-D plane with a pixel resolution of 40 µm in the axial dimension and 60 µm in the lateral dimension.

The visualization and image processing is illustrated in Figure 3. Six B-mode ultrasound frames were acquired with the first frame occurring before the HIFU pulse. The ultrasound image acquired before HIFU was used to determine the background signal, while the ultrasound images acquired post-HIFU were used to visualize the vaporization and recondensation processes. A differential of frames, shown in Figure 3(b), between pre-HIFU ultrasound and the first frame after HIFU exposure was used to isolate the signal from the vaporization of the HnDs. Hereafter, images with the red, yellow and black colormap are from the vaporization differential (i.e., the second ultrasound frame minus the first). The ultrasound signal of the nanodroplets was quantified over a 3.94x3.94 mm square focal spot. The total signal amplitude is defined as the sum of all pixel values in the square region of interest. This dynamic ultrasound signal is directly related to the number of microbubbles in focal area at each point in time. By tracking the focal area over consecutive frames, shown in Figure 3(c), the signal amplitude provides a visualization of nanodroplet activity in the focal area before and after a HIFU pulse.

F. Nanodroplet Characterization

The nanodroplets were characterized via dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments,

---

Fig. 3. Illustration of image visualization and processing. (a) Ultrasound B-mode image frames of HnDs, shown in grayscale, are collected via the Verasonics high frequency transducer. One frame is collected pre-HIFU and five frames post-HIFU. (b) The difference between post-HIFU and pre-HIFU frames highlights the microbubbles resulting from nanodroplet vaporization and is shown in figures with a red to black colormap. (c) B-mode images are processed by taking the sum of pixel amplitudes in a square containing the HIFU focal area and condensed into a frame by frame graph. This graph helps illustrate vaporization and recondensation of HnDs.
Inc., Westborough, MA, USA). The three types of perfluorocarbon nanodroplets used in this study are perfluoropentane (PnDs), perfluorohexane (HnDs) and perfluorooctyl bromide (OBnDs). The nanodroplets were diluted 1:100 in DI Water. Three measurements with 12 recordings each were averaged together for each sample vial. A total of three different sample vials were measured per type of nanodroplet. The sample vials were measured at 20 °C. The concentrations and polydispersity index were determined by the Zetasizer Nano software.

A separate DLS characterization experiment examined the size of microbubbles and nanodroplets produced via vaporization. Another 3 samples of PnDs and HnDs were measured before and after HIFU vaporization. Each sample was measured three times before and three times after with 12 recordings each measurement. The resulting intensity data was averaged together. The HIFU vaporization was done through a thin parafilm medium so as to minimize acoustic attenuation while in the DLS measurement cassette. Over 5 seconds, 50 pulses of 10 cycle, 1.1 MHz HIFU at 10.5 MPa were used to vaporize the 1 ml volume of 1:100 nanodroplets in DI water.

**G. Phantom Experiments**

Three phantom experiments were performed. Phantoms were prepared with nanodroplets as previously described. The first set of experiments examined the behavior of PFCnDs with different perfluorocarbon cores. The second mapped out the temperature-dependent vaporization thresholds of HnDs. The third set explored the limits of repeated vaporization of HnDs.

For the first set of experiments five phantoms were prepared for each of four groups: PFCnD-free (blank) phantoms, PnD phantoms, HnD phantoms, and OBnD phantoms. Blank phantoms acted as a negative control to track possible cavitation induced solely by HIFU. The PnD phantoms, with a lower boiling point perfluorocarbon, served to visualize the behavior of PFCnDs with only a single vaporization event. The OBnD phantoms allowed for the investigation of PFCnDs with a higher boiling point of 142 °C (and thus higher activation threshold). Each phantom was imaged three times at room temperature with the previously described activation sequence to visualize repeated vaporization. Each HIFU pulse was separated from the next by 5 ms. As supported by literature, there was no change in temperature from the HIFU pulse as measured by a thermocouple (Heidolph, Schwabach, Germany) [43]. The blank, HnD and OBnD phantoms were triggered with 10.5 MPa PNP (I_{SPPA} = 3057 W/cm²) while the PnDs were triggered with 8.4 MPa PNP (I_{SPPA} = 1956 W/cm²). The lower PNP for PnDs was used to prevent possible excess cavitation of the PnDs. The PNP levels were applied to a single spot with a 30 s interval. The HIFU was applied to the same spot to investigate the robustness of HnDs over the course of multiple vaporization/recondensation cycles. The phantom was imaged at defined intervals after 0, 100, 750, 1,500, and 10,000 HIFU pulses.

**III. Results**

The PFCnDs exhibited similar sub-micron size distributions. The averaged peak diameter for the PnD samples was 492.24 ± 39.85 nm at an average concentration of 2.4 ± 10^8 particles/mL and a Polydispersity index (PDI) of 0.208 ± 0.036. The averaged peak diameter for the HnD samples was 558.71 ± 31.58 nm at an average concentration of 1.8 ± 10^8 particles/mL and a PDI of 0.229 ± 0.022. The averaged peak diameter for the OBnD samples was 455.93 ± 58.25 nm at an average concentration of 1.4 ± 10^8 particles/mL and a PDI of 0.184 ± 0.026.
an average concentration of $2.9 \times 10^8$ particles/mL and a PDI of 0.270 ± 0.062.

A separate experiment was conducted to examine the change in size distribution due to HIFU. Figure 4 presents the average intensity mode data of PnDs and HnDs before and after HIFU vaporization. 50 pulses of 10 cycle, 1.1 MHz HIFU at 10.5 MPa were used to vaporize the 1 ml solution of PnDs and HnDs. A portion of PnDs remained microbubbles after vaporization. The microbubbles had an averaged peak diameter and HnDs. A portion of PnDs remained microbubbles after 10.5 MPa were used to vaporize the 1 ml solution of PnDs and HnDs. A portion of PnDs remained microbubbles after vaporization. The microbubbles had an averaged peak diameter of 4.6 ± 0.4 µm for a 10 fold increase in size from the PnDs. This was seen on a scale of approximately five minutes during the 3 measurements of 12 recordings post-vaporization. The HnDs post-vaporization remained nanodroplets with a similar but slightly decreased intensity distribution.

To demonstrate that HnDs can be repeatedly vaporized with HIFU, we first confirmed that ultrasound signal in the HIFU focus requires the presence of activatable PFCnDs and that the repeatable vaporization is due to the high boiling point perfluorocarbon core. To this end, PA phantoms were prepared containing no nanodroplets, PnDs, HnDs or OBnDs. Figure 5(a) shows examples of differential ultrasound images acquired with three consecutive HIFU pulses for each of the four phantom groups. There was no apparent ultrasound signal increase in the blank or OBnD phantoms for any of the HIFU pulses. OBnDs, with a high core boiling point, served as a secondary control to test whether cavitation was occurring due to the nanodroplets acting as nucleation sites. In the phantoms with PnDs, the first HIFU pulse triggered many of the nanodroplets resulting in the visible echogenic cloud. Subsequent HIFU pulses failed to produce more microbubbles as most nanodroplets in the focal spot were already vaporized. The representative HnD image set demonstrates the repeatable acoustic vaporization of HnDs compared to PnDs. Each HIFU pulse produced a similar vaporization response from the HnDs.

Figure 5(b) and 5(c) further illustrate the principal results of these images. Figure 5(b) tracks the total sum of ultrasound signal amplitude in the focal area over a three HIFU vaporization events in a 16-frame ultrasound imaging sequence. The HIFU pulses occur prior to ultrasound frames 2, 7, and 12. PnDs vaporize on the first HIFU pulse with slight increases on the second and third pulses. This is consistent with PnD activity in literature [26], [32], [58], [59]. HnDs vaporize after each HIFU pulse and the nanodroplets quickly recondense resulting in decaying ultrasound signal after each peak. Figure 5(c) shows the increase in ultrasound signal magnitude after three HIFU stimuli averaged over five phantoms. The averaged differential amplitudes show HnDs creating microbubbles with each pulse, PnDs vaporizing primarily on the first HIFU pulse, and no ultrasound signal from both OBnDs and blank phantoms. Taken together, these results show that HnDs can be reliably and repeatedly vaporized with a HIFU stimulus.

The thresholds for vaporization of HnDs were further examined in Figure 6. A sufficiently large PNP from the HIFU is required to overcome the vaporization pressure of the high boiling point of perfluorohexane. HnD phantoms were subjected to HIFU pulses with increasing amplitude at 0 °C, 23 °C, and 37 °C. Graphs for the three tested temperatures, Figure 6(a,b,c), were created by imaging vaporization in seven phantoms with 3 HIFU pulses per tested PNP. At 0 °C (Figure 6(a)), the HnDs showed no vaporization activity at less than 11.3 MPa. At PNP of 11.3 MPa and greater, two of the seven low-temperature phantoms exhibited a degree of vaporization onward while five showed no activity. Vaporization began at 9 MPa in 23 °C phantoms (Figure 6(b)) and at 8 MPa in 37 °C phantoms (Figure 6(c)).

While the degree of vaporization varied by phantom and by focal spot, there was a stark contrast between microbubble signal and the noise level of the system. To more readily visualize the vaporization data, Figure 6(d) reframes the data from Figure 6(a,b,c) and presents the percentage of HIFU pulses at each PNP whose differential amplitude was over a threshold. The threshold (1.5 × 10^7 in differential amplitude) was defined as 5% of the max recorded vaporization signal. The percentage was chosen to selectively identify vaporization
Fig. 6. Vaporization of HnDs is shown by the mean differential amplitude for seven phantoms over 21 PNPs. Standard deviation is shown by the shaded area. The vaporization thresholds are tested at 0 °C, 23 °C, and 37 °C shown in (a), (b), and (c) respectively. (d) A visualization of the percent chance for vaporization for the three temperatures with increasing HIFU PNP. Th-1 is the 10.5 MPa PNP threshold at which the rest of the room temperature HnD experiments were conducted. Th-2 is the 12.2 MPa threshold at which residual signal was seen after vaporization in the 37 °C phantoms.

in phantoms and exceed the variability in baseline signals arising from system noise and phantom preparation. The threshold for 100% reliable activation at room temperature is 10.5 MPa, marked as Th-1 in Figure 6(d). Th-2 of 12.2 MPa in Figure 6(d), marks the level at which higher PNPs caused an irreversible signal increase in the phantoms at 37 °C that is indicative of mechanical damage.

The primary motivation for using a high boiling point perfluorocarbon is the prospect of sustained imaging of PFC-nDs. Thus, we investigated the number of HnD vaporization/recondensation cycles which could be reasonably imaged. This experiment was done at room temperature to ensure temperature stability of the phantom over the long duration of this experiment. Based on the results from Figure 6, a PNP of 10.5 MPa was used to ensure vaporization of HnDs. The phantom was kept static so as to repeatedly vaporize the same population of HnDs in the HIFU focus. The phantoms were continually pulsed with HIFU at 10 Hz and imaged after exposure to 0, 100, 750, 1,500, and 10,000 HIFU pulses. Figure 7(a) shows representative examples of vaporization and recondensation after each number of HIFU pulses to test the diminishing vaporization response and durability of the nanodroplets. The signal amplitude was not normalized to show the consistent signal in the pre-HIFU US frame. The characteristic exponential decay of ultrasound signal in frames 2-6 is due to the stochastic recondensation of the HnDs after the HIFU-induced vaporization. Figure 7(b) shows the pre-HIFU and post-HIFU B-mode ultrasound frames at each of these time points. Fewer microbubbles are created over time as more HIFU pulses are applied. Shown by the pre-HIFU frames remaining constant, even after the 10,000 HIFU pulses there was no widespread visible damage to the phantom. Figure 7(c) shows the averaged signal amplitude of this repeated vaporization experiment from three phantoms. The HnD signal amplitude gradually decreases over the course of hundreds to thousands of vaporization events. These data show that the HnDs remain highly stable even after minutes of sustained HIFU-induced vaporization.

IV. DISCUSSION

This work demonstrates high-amplitude, short pulses with a 1.1-MHz single-element HIFU transducer can overcome the relatively high ADV threshold of HnDs. This waveform has a similar pulse duration to mechanical tissue disruption techniques, such as lithotripsy and histotripsy [60]. The short pulse duration employed by these methods has been shown to result in a negligible temperature rise in the tissue [42], [43]. Given that the current work uses much lower pressure levels, it is unlikely that thermal tissue damage will occur.
Despite the comparatively lower HIFU energies, the potential for mechanical damage via cavitation still exists. As shown in Figure 6(c), the minimum PNP at body temperature for activation is approximately 8 MPa, which corresponds to a mechanical index of 7.6. This pressure is well below reported thresholds of 13.7 to 21 MPa for 1.1-MHz ultrasound cavitation in tissue [48], but the mechanical index is above the accepted diagnostic ultrasound imaging threshold of 1.9 [61]. While the cavitation threshold depends on experimental variables such as dissolved gas content, nucleation sites, and water concentration [26], [30], [47], [59], [62], we found the energy levels required for HnD vaporization to be low enough so as to not cause cavitation in either blank phantoms or the OBnD-loaded phantoms with nanodroplet nucleation sites.

Figure 6 shows a decreasing vaporization threshold with increasing temperature. The acoustic vaporization threshold varies with temperature because environmental temperature affects the pressure required to instigate the phase change and overcome the perfluorocarbon boiling point and stabilizing Laplace pressure. The temperature dependence of ADV lowers the activation threshold to 8 MPa at body temperature. Therefore, a transition to in-vivo work would require a smaller PNP than the other studies conducted in this work, which were performed at room temperature. It is important to note this threshold is also dependent on the imaging environment. Phantom damage was only observed in the case of PNPs greater than 12.2 MPa in HnD phantoms at 37 °C. We hypothesize that this could be the result of a more violent vaporization process, or ultrasonic cavitation after the initial formation of microbubbles. Further testing of the bioeffects is needed in order to safely apply the technique in-vivo.

An interesting observation is the decreased signal from the HnDs after many vaporization cycles as shown in Figure 7(c). Although the mechanism of degradation requires further study, we hypothesize that with each activation of the HnDs there is the possibility that an amount of perfluorocarbon escapes with each microbubble transition cycle. This is supported by the smaller mean hydrodynamic diameter of the HnDs after exposure to HIFU (Fig. 4b). The acoustic vaporization threshold for phase change particles varies greatly in literature [21], [24], [25], [33], [47], [63], [64]. The perfluorocarbon core boiling point is one clear factor, but size, the Laplace pressure, shell composition, and phantom stiffness also play a role in this threshold. While PFCnDs can be synthesized with diameters of smaller than 200 nm, using larger nanodroplets could decrease the activation energy threshold [65]. This is due to a lower Laplace pressure counteracting vaporization [58], [66]. Therefore, a decreasing hydrodynamic diameter due to loss of perfluorocarbon to the surrounding environment implies the PFCnD might no longer activate in response to the same amplitude of HIFU energy. More investigation of this proposed rationale behind the loss of signal seen over time in Figure 7 could provide insight into the mechanisms of nanodroplet vaporization and recondensation.

V. CONCLUSION

Phase change nanodroplets have great potential as multifunctional, nano-sized ultrasound contrast agents. We systematically studied the acoustic droplet vaporization of high boiling point perfluorocarbon nanodroplets and identified their ability to recondense. Benefits of acoustic activation were highlighted to bring perfluorohexane phase change nanodroplet detection to clinically relevant depths. The ADV threshold was shown to lower with increasing temperature, reducing the energy requirements to apply these particles in-vivo. Rapid, repeated vaporization of these particles provides a platform for clinically relevant tracking of blinking particles and their kinetics.

ACKNOWLEDGMENT

The authors would like to thank Prof. Tyrone Porter from the University of Texas for the needle hydrophone measurements of our experimental setup. Support was provided by NIH grant R21CA197409 and by a Prouty Pilot Grant from the Norris Cotton Cancer Center.

REFERENCES

[1] R. Gessner and P. A. Dayton, “Advances in molecular imaging with Ultrasound,” pp. 117–127, 5 2010.
[2] K. Ferrara, R. Pollard, and M. Borden, “Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery,” Annu Rev Biomed Eng, vol. 9, pp. 415–447, 2007. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/17651012 http://www.annualreviews.org/pdf/doi/10.1146/annurev.bioeng.8.061505.095852
[3] V. Sboros and M. X. Tang, “The assessment of microvascular flow and tissue perfusion using ultrasound imaging,” Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, vol. 224, no. 2, pp. 273–290, 2 2010.
[4] R. P. Stride and C. C. Coussios, “Cavitation and contrast: The use of bubbles in ultrasound imaging and therapy,” Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, vol. 224, no. 2, pp. 171–191, 2 2010.
[5] N. McDannold, Y. Z. Zhang, C. Power, F. Jolesz, and N. Vykhotdeseva, “Nonthermal ablation with microbubble-enhanced focused ultrasound close to the optic tract without affecting nerve function,” Journal of Neurosurgery, vol. 119, no. 5, pp. 1208–1240, 11 2013.
[6] K. E. Hitchcock and C. K. Holland, “Ultrasound-assisted thrombolysis for stroke therapy: Better thrombus break-up with bubbles,” in Stroke, vol. 41, no. 10 SUPPL. 1, 10 2010.
[7] A. L. Klibanov, “Microbubble contrast agents: Targeted ultrasound imaging and ultrasound-assisted drug-delivery applications,” pp. 354–362, 3 2006.
[8] K. B. Bader, G. Bouchoux, and C. K. Holland, “Sonothrombolysis,” pp. 339–362, 1 2016.
[9] D. H. Simpson, C. T. Chin, and P. N. Burns, “Pulse inversion Doppler: a new method for detecting nonlinear echoes from microbubble contrast agents,” Ultrasounds, Ferroelectrics and Frequency Control, IEEE Transactions on, vol. 46, no. 2, pp. 372–382, 1999.
[10] W. T. Shi and F. Forsberg, “Ultrasound characterization of the nonlinear properties of contrast microbubbles,” Ultrasound in Medicine and Biology, vol. 26, no. 1, pp. 93–104, 1 2000.
[11] E. Quaiwa, “Microbubble ultrasound contrast agents: an update,” Eur Radiol, vol. 17, no. 8, pp. 1995–2008, 2007. [Online]. Available: http://www.ncbi.nlm.nih.gov/pubmed/17351779
[12] R. Campbell, “Tumor Physiology and Delivery of Nanopharmaceuticals,” Anti-Cancer Agents in Medicinal Chemistry, vol. 6, no. 6, pp. 503–512, 4 2008.
[13] P. S. Sheeran, N. Matsuura, M. A. Borden, R. Williams, T. O. Matsunaga, P. N. Burns, and P. A. Dayton, “Methods of Generating Submicrometer Phase-Shift Perfluorocarbon Droplets for Applications in Medical Ultrasonography,” IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 64, no. 1, pp. 252–263, 1 2017. [Online]. Available: https://ieeexplore.ieee.org/document/7604095/
[14] K. Wilson, K. Homan, and S. Emelianov, “Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging,” Nat Commun, vol. 3, p. 618, 2012. [Online]. Available: http://dx.doi.org/10.1038/ncomms1627 http://www.nature.com/ncomms/journal/v3/n1/pdf/ncomms1627.pdf
This article has been accepted for publication in a future issue of this journal, but has not been fully edited. Content may change prior to final publication. Citation information: DOI 10.1109/TUFFC.2021.3093828, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control
[53] M. J. Choi, S. R. Guntur, K. I. Lee, D. G. Paeng, and A. Coleman, “A Tissue Mimicking Polyacrylamide Hydrogel Phantom for Visualizing Thermal Lesions Generated by High Intensity Focused Ultrasound,” Ultrason in Medicine and Biology, vol. 39, no. 3, pp. 439–448, 2013. [Online]. Available: http://dx.doi.org/10.1016/j.ultrasmedbio.2012.10.002

[54] R. Asami, T. Ikeda, T. Azuma, S. Umemura, and Ken-Ichi Kawabata, “Acoustic signal characterization of phase change nanodroplets in tissue-mimicking phantom gels,” Japanese Journal of Applied Physics, vol. 49, no. 7 PART 2, p. 07HF16, 2010. [Online]. Available: https://iopscience.iop.org/article/10.1143/JJAP.49.07HF16

[55] R. Song, C. Peng, X. Xu, R. Zou, and S. Yao, “Facile fabrication of uniform nanoscale perfluorocarbon droplets as ultrasound contrast agents,” Microfluidics and Nanofluidics, vol. 23, no. 1, p. 12, 1 2019. [Online]. Available: https://doi.org/10.1007/s10404-018-2172-z

[56] A. S. Hannah, D. VanderLaan, Y.-S. Chen, and S. Y. Emelianov, “Photoacoustic and ultrasound imaging using dual contrast perfluorocarbon nanodroplets triggered by laser pulses at 1064 nm,” Biomedical Optics Express, vol. 5, no. 9, pp. 3042–3052, 2014.

[57] L. C. Phillips, C. Puett, P. S. Sheeran, P. A. Dayton, G. Wilson Miller, and T. O. Matsunaga, “Phase-shift perfluorocarbon agents enhance high intensity focused ultrasound thermal delivery with reduced near-field heating,” The Journal of the Acoustical Society of America, vol. 134, no. 2, pp. 1473–1482, 2013. [Online]. Available: http://asa.scitation.org/doi/10.1121/1.4812866

[58] N. Y. Rapoport, A. M. Kennedy, J. E. Shea, C. L. Scaife, and K.-H. Nam, “Controlled and targeted tumor chemotherapy by ultrasound-activated nanodroplets/microbubbles,” Journal of Controlled Release, vol. 138, no. 3, pp. 268–276, 2009.

[59] N. Reznik, O. Shpak, E. C. Gelderblom, R. Williams, N. De Jong, M. Versluis, and P. N. Burns, “The efficiency and stability of bubble formation by acoustic vaporization of submicron perfluorocarbon droplets,” in Ultrascronics, vol. 53, no. 7. Elsevier, 9 2013, pp. 1368–1376.

[60] T. Ikeda, S. Yoshizawa, N. Koizumi, M. Mitsuishi, and Y. Matsumoto, “Focused ultrasound and lithotripsy,” in Advances in Experimental Medicine and Biology. Springer New York LLC, 2016, vol. 880, pp. 113–129. [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/26486335/

[61] T. Şen, O. Tufekçioğlu, and Y. Koza, “Mechanical index,” Anadolu Kardiyojoloji Dergisi, vol. 15, no. 4, pp. 334–336, 2015. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336845/

[62] S. Raut, M. Khairalseed, A. Honari, S. R. Sirsi, and K. Hoyt, “Impact of hydrostatic pressure on phase-change contrast agent activation by pulsed ultrasound,” Citation: The Journal of the Acoustical Society of America, vol. 145, p. 3457, 2019.

[63] T. Giesecke and K. Hynynen, “Ultrasound-mediated cavitation threshold of liquid perfluorocarbon droplets in vitro,” Ultrason in Medicine & Biology, vol. 29, no. 9, pp. 1359–1365, 9 2003.

[64] M. Aliabouzah, K. N. Kumar, and K. Sarkar, “Effects of droplet size and perfluorocarbon boiling point on the frequency dependence of acoustic vaporization threshold,” The Journal of the Acoustical Society of America, vol. 145, no. 2, pp. 1105–1116, 2 2019.

[65] O. D. Kripfgans, M. L. Fabiilli, P. L. Carson, and J. B. Fowlkes, “On the acoustic vaporization of micrometer-sized droplets,” The Journal of the Acoustical Society of America, vol. 116, no. 1, pp. 272–281, 2004.

[66] P. S. Sheeran, S. Luois, P. A. Dayton, and T. O. Matsunaga, “Formulation and acoustic studies of a new phase-shift agent for diagnostic and therapeutic ultrasound,” Langmuir, vol. 27, no. 17, pp. 10412–10420, 2011. [Online]. Available: http://pubs.acs.org/doi/pdfplus/10.1021/la103705